Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$198 Mln
P/E Ratio
--
P/B Ratio
6.35
Industry P/E
--
Debt to Equity
0.21
ROE
-0.96 %
ROCE
-79.95 %
Div. Yield
0 %
Book Value
2.89
EPS
-2.8
CFO
$-109.07 Mln
EBITDA
$-108.68 Mln
Net Profit
$-128.80 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
MediWound - ADR
| 2.02 | 13.86 | -9.52 | -0.44 | 8.52 | 6.09 | -8.85 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
MediWound - ADR
| -24.61 | -18.34 | -36.22 | 19.35 | -23.65 | -8.72 | -2.82 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 6.60 | 381.83 | 26.56 | 5.74 | |
| 2.44 | 4.43 | -- | -321.92 | |
| 2.62 | 27.16 | -- | -1038.73 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a... biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Address: 42 Hayarkon Street, Yavne, Israel, 8122745 Read more
Chief Financial Officer
Ms. Hani Luxenburg
Chief Financial Officer
Ms. Hani Luxenburg
Headquarters
Yavne
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of MediWound Ltd - ADR stood at $ 73 Mln as on 31-Dec-24
The share price of MediWound Ltd - ADR is $18.16 (NASDAQ) as of 29-Apr-2025 16:00 EDT. MediWound Ltd - ADR has given a return of 8.52% in the last 3 years.
MediWound Ltd - ADR has a market capitalisation of $ 198 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of MediWound Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the MediWound Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of MediWound Ltd - ADR.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Address: 42 Hayarkon Street, Yavne, Israel, 8122745
The CEO & director of Ms. Hani Luxenburg. is MediWound Ltd - ADR, and CFO & Sr. VP is Ms. Hani Luxenburg.
There is no promoter pledging in MediWound Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
35
|
|
|
2
|
|
|
0
|
|
|
35
|
| MediWound Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-96.33
|
|
Operating margin(%)
|
-145.44
|
|
Net Margin(%)
|
-149.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of MediWound Ltd - ADR was $0 Mln.
$-0.13
(
